Cardinal Health's Medical Segment Boss Sold $8 Million in Stock. Here's What to Know
Key Points
The disposition of 35,000 shares on August 18 generated a total transaction value of $8.3 million.
The transaction involved exclusively directly held shares, with the insider reporting no indirect ownership in this filing.
The divestment follows a one-year total return of 57% for the stock as of the transaction date.
Stephen M. Mason, CEO of the firm's GMPD Segment, sold 35,000 shares of Cardinal Health, Inc. (NYSE:CAH) on August 18, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $8.3 million |
| Shares sold | 35,000 |
| Post-transaction shares (directly held) | 18,061 |
| Post-transaction value | $4.24 million |
Transaction value based on SEC Form 4 weighted average sale price ($236.40); post-transaction value based on the August 18 market close ($234.98).
Key questions
- What is the scale of this transaction relative to the insider's remaining position?
The sale of 35,000 shares represents a majority of the insider's position, leaving a direct holding of 18,061 shares. These remaining shares have a market value of $4.24 million based on the August 18 market close. - How has the stock performed leading up to this transaction?
As of the transaction date, the company has seen a one-year total return of 57%. The sale was executed at a weighted average price of $236.40 per share, while the stock finished the following day, August 19, at $234.85. - What is the company's current financial profile and market standing?
Cardinal Health reports a market capitalization of $55.0 billion. For the most recent trailing-twelve-month period, the company generated $254.2 billion in revenue and $1.7 billion in net income.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $234.85 |
| Market Capitalization | $55.0 billion |
| Revenue (TTM) | $254.2 billion |
| Net Income (TTM) | $1.7 billion |
Company Snapshot
- Cardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical products, and healthcare services across the United States, Canada, Europe, Asia, and other international markets.
- The company generates revenue through its two core divisions--Pharmaceutical and Medical--which provide distribution, logistics, and value-added services to hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, and physician practices.
- Cardinal Health serves a diverse customer base, including healthcare providers, hospital systems, retail and specialty pharmacies, outpatient surgical centers, clinical laboratories, and physician practices, with additional reach into home healthcare and patient populations.
Cardinal Health is one of the largest healthcare services and products companies globally, with a TTM revenue base of $254.2 billion and a market capitalization of $55.0 billion. The company maintains a competitive advantage through its integrated distribution network, scale across pharmaceutical and medical segments, and established relationships with a broad spectrum of healthcare providers across multiple geographies. Cardinal Health is positioned as a critical infrastructure provider within the healthcare supply chain, supporting the delivery of care across institutional and individual patient settings.
What this transaction means for investors
Mason cut his own position by 29% across August's award cycle, a steeper reduction than either the CEO or the CFO took. He went into the Aug. 4 performance-unit award holding 25,490 shares and came out the far side with 18,061, and he did roughly the same thing last August, selling 42,635 shares for about $6.2 million. So the habit isn't new, but the base seems to keep shrinking.
Meanwhile, he's running the segment that's still being fixed. Global Medical Products and Distribution posted $3.1 billion of fourth-quarter revenue, down 2%, and reported profit of $150 million that falls to $50 million once you strip out a one-time refund on emergency-powers tariffs that have since been replaced. CFO Aaron Alt said on the Aug. 11 earnings call that "this industry and our business remain a work in progress." Based on projections, fiscal 2027 asks for $200 million to $220 million from the segment, and Alt already told analysts that a drawn-out Iran conflict would push it to the low end. Meanwhile the profit is weighted to the back half of the year, so the fourth quarter will be critical to understand how projections ultimately hold up.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.